Managing endothelial dysfunction in COVID‐19 with statins, beta blockers, nicorandil, and oral supplements: A pilot, double‐blind, placebo‐controlled, randomized clinical trial
Abstract Coronavirus disease 2019 (COVID‐19) is associated with endothelial dysfunction. Pharmacologically targeting the different mechanisms of endothelial dysfunction may improve clinical outcomes and lead to reduced morbidity and mortality. In this pilot, double‐blind, placebo‐controlled, randomi...
Main Authors: | Kamal Matli, Abdulrahman Al Kotob, Wassim Jamaleddine, Soad Al Osta, Pascale Salameh, Rami Tabbikha, Nibal Chamoun, Ahmad Moussawi, Jean‐Michel Saad, Gibran Atwi, Tarik Abu Saad, Omar Jamal, Jacques Mokhbat, Georges Ghanem |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-10-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.13369 |
Similar Items
-
Effects of statins on clinical outcomes in hospitalized patients with community-acquired pneumonia
by: Rony M. Zeenny, et al.
Published: (2020-08-01) -
Combination of Nicorandil and Beta-Adrenergic Receptor Blockers in Patients with Coronary Artery Disease: A Real-World Observational Study
by: Jia Cheng MD, PhD, et al.
Published: (2023-09-01) -
PHARMACOLOGICAL PRECONDITIONING. FOCUS ON NICORANDIL
by: R. V. Gostishchev, et al.
Published: (2017-10-01) -
Nicorandil in clinical cardiology practice
by: article Editorial
Published: (2012-02-01) -
Enoxaparin 20 mg for thromboprophylaxis in severe renal impairment
by: Lamis R. Karaoui, et al.
Published: (2019-01-01)